Trial reportScientific reports2017
Multiple fresh fecal microbiota transplants induces and maintains clinical remission in Crohn's disease complicated with inflammatory mass.
Trial report in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01793831 (Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn&Apos;s Diseases), which is not on this map. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Standardized Fecal Microbiota Transplantation for Moderate to Severe Crohn&Apos;s Diseases
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The Role of Microbiota and Fecal Transplantation in Inflammatory Bowel Disease.Pathogens (Basel, Switzerland) · 2026Pooled it
- Fecal microbiota transplantation for induction of remission in Crohn's disease: a systematic review and meta-analysis.International journal of colorectal disease · 2023Pooled it
- Efficacy of faecal microbiota transplantation in Crohn's disease: a new target treatment?Microbial biotechnology · 2020Trial
- Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study.Microbiome · 2020Trial
- Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn's disease.Applied microbiology and biotechnology · 2019Trial
- The Safety of Fecal Microbiota Transplantation for Crohn's Disease: Findings from A Long-Term Study.Advances in therapy · 2018Trial
- Role of the gut microbiota-bile acid axis in liver fibrosis based on microbiomics and targeted metabolomics.BMC microbiology · 2026Article
- Uncovering the role of microbiota and fecal microbiota transplantation in Crohn's disease: Current advances and future hurdles.World journal of methodology · 2025Review
- The Role of Gut Microbiota in Gastrointestinal Immune Homeostasis and Inflammation: Implications for Inflammatory Bowel Disease.Biomedicines · 2025Review
- Gut microbiota dysbiosis in inflammatory bowel disease: interaction with intestinal barriers and microbiota-targeted treatment options.Frontiers in cellular and infection microbiology · 2025Review
- The gut microbiota and its metabolites: novel therapeutic targets for inflammatory bowel disease.Frontiers in immunology · 2025Review
- Unraveling the Microbiome-Human Body Axis: A Comprehensive Examination of Therapeutic Strategies, Interactions and Implications.International journal of molecular sciences · 2024Review
- Current perspectives on fecal microbiota transplantation in inflammatory bowel disease.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2024Review
- Refractory Crohn's Disease: Perspectives, Unmet Needs and Innovations.Clinical and experimental gastroenterology · 2024Review
- Review
- Clinical Effects of Faecal Microbiota Transplantation as Adjunctive Therapy in Dogs with Chronic Enteropathies-A Retrospective Case Series of 41 Dogs.Veterinary sciences · 2023Article
- Repeated and multiple fecal microbiota transplantations plus partial enteral nutrition as the first-line treatment in active pediatric Crohn's disease.Frontiers in cellular and infection microbiology · 2023Article
- Washed preparation of faecal microbiota changes the transplantation related safety, quantitative method and delivery.Microbial biotechnology · 2022Article
- Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases.Journal of clinical medicine · 2022Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ancient Chinese medical literature, as well as our prior clinical experience, suggests that fecal microbiota transplantation (FMT) could treat the inflammatory mass. We aimed to evaluate the efficacy and safety of multiple fresh FMTs for Crohn's disease (CD) complicated with intraabdominal inflammatory mass. The "one-hour FMT protocol" was followed in all patients. Twenty-five patients were diagnosed with CD and related inflammatory mass by CT or MRI. All patients received the initial FMT followed by repeated FMTs every 3 months. The primary endpoint was clinical response (improvement and remission) and sustained clinical remission at 12 months. Secondary endpoints were improvement in size of phegmon/abscess based upon cross-sectional imaging and safety of FMT. 68.0% (17/25) and 52.0% (13/25) of patients achieved clinical response and clinical remission at 3 months post the initial FMT, respectively. The proportion of patients at 6 months, 12 months and 18 months achieving sustained clinical remission with sequential FMTs was 48.0% (12/25), 32.0% (8/25) and 22.7% (5/22), respectively. 9.5% (2/21) of patients achieved radiological healing and 71.4% (15/21) achieved radiological improvement. No severe adverse events related to FMT were observed. This pragmatic study suggested that sequential fresh FMTs might be a promising, safe and effective therapy to induce and maintain clinical remission in CD with intraabdominal inflammatory mass.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.